Cargando…

Thrombin generation and implications for hemophilia therapies: A narrative review

Thrombin plays an essential role in achieving and maintaining effective hemostasis and stable clot formation. In people with hemophilia, deficiency of procoagulant factor (F)VIII or FIX results in insufficient thrombin generation, leading to reduced clot stability and various bleeding manifestations...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sidonio, Robert F., Hoffman, Maureane, Kenet, Gili, Dargaud, Yesim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9926221/ https://www.ncbi.nlm.nih.gov/pubmed/36798897 http://dx.doi.org/10.1016/j.rpth.2022.100018

Ejemplares similares

Recombinant porcine factor VIII corrects thrombin generation in vitro in plasma from patients with congenital hemophilia A and inhibitors
por: Négrier, Claude, et al.
Publicado: (2022)

Thrombin generation for monitoring hemostatic therapy in hemophilia A: A narrative review
por: Verhagen, Marieke J. A., et al.
Publicado: (2022)

Clinical Utility of Subcutaneous Factor VIII Replacement Therapies in Hemophilia A: A Review of the Evidence
por: Dargaud, Yesim, et al.
Publicado: (2021)

Recombinant porcine factor VIII: Lessons from the past and place in the management of hemophilia A with inhibitors in 2021
por: Dargaud, Yesim, et al.
Publicado: (2021)

Reversal of rivaroxaban anticoagulant effect by prothrombin complex concentrates: which dose is sufficient to restore normal thrombin generation?
por: Giffard-Quillon, Lorine, et al.
Publicado: (2020)

Thrombin generation, bleeding and hemostasis in humans: Protocol for a scoping review of the literature
por: Shaw, Joseph R., et al.
Publicado: (2023)

Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: Combining thrombin and plasmin generation
por: Valke, Lars L.F.G., et al.
Publicado: (2020)

Managing Severe Hemophilia A in Children: Pharmacotherapeutic Options
por: Regling, Katherine, et al.
Publicado: (2022)

Women with Hemophilia: Case Series of Reproductive Choices and Review of Literature
por: Lalezari, Shadan, et al.
Publicado: (2021)

Association between Thrombin Generation and Clinical Characteristics in COVID-19 Patients
por: Cohen, Omri, et al.
Publicado: (2023)

In patients with hemophilia, a decreased thrombin generation profile is associated with a severe bleeding phenotype
por: Verhagen, Marieke J.A., et al.
Publicado: (2023)

Past, present and future of hemophilia: a narrative review
por: Franchini, Massimo, et al.
Publicado: (2012)

Thrombin Activatable Fibrinolysis Inhibitor (TAFI): An Updated Narrative Review
por: Sillen, Machteld, et al.
Publicado: (2021)

Applicability of the Thrombin Generation Test to Evaluate the Hemostatic Status of Hemophilia A Patients in Daily Clinical Practice
por: Bernardo, Ángel, et al.
Publicado: (2022)

Potentiation of Thrombin Generation in Hemophilia A Plasma by Coagulation Factor VIII and Characterization of Antibody-Specific Inhibition
por: Doshi, Bhavya S., et al.
Publicado: (2012)

The impact of prothrombin complex concentrates when treating DOAC-associated bleeding: a review
por: Hoffman, Maureane, et al.
Publicado: (2018)

Four Decades of Carrier Detection and Prenatal Diagnosis in Hemophilia A: Historical Overview, State of the Art and Future Directions
por: Dardik, Rima, et al.
Publicado: (2023)

Mode of delivery in hemophilia: vaginal delivery and Cesarean section carry similar risks for intracranial hemorrhages and other major bleeds
por: Andersson, Nadine G., et al.
Publicado: (2019)

Thromboelastography and thrombin generation assessments for pediatric severe hemophilia A patients are highly variable and not predictive of clinical phenotypes
por: Mathews, Natalie, et al.
Publicado: (2022)

Efficacy and safety of next-generation tick transcriptome-derived direct thrombin inhibitors
por: Koh, Cho Yeow, et al.
Publicado: (2021)

Real-World Data on Bleeding Patterns of Hemophilia A Patients Treated with Emicizumab
por: Levy-Mendelovich, Sarina, et al.
Publicado: (2021)

Long‐term safety and efficacy of N8‐GP in previously treated pediatric patients with hemophilia A: Final results from pathfinder5
por: Šaulytė Trakymienė, Sonata, et al.
Publicado: (2020)

Management of surgery in persons with hemophilia A receiving emicizumab prophylaxis: data from a national hemophilia treatment center
por: Cohen, Omri, et al.
Publicado: (2023)

The safety and efficacy of N8-GP (turoctocog alfa pegol) in previously untreated pediatric patients with hemophilia A
por: Male, Christoph, et al.
Publicado: (2022)

Factor VIII inhibitors in hemophilia A treated with emicizumab: longitudinal follow-up of outcomes
por: Levy-Mendelovich, Sarina, et al.
Publicado: (2023)

Thrombin Generation and Cancer: Contributors and Consequences
por: Reddel, Caroline J., et al.
Publicado: (2019)

A review of commercially available thrombin generation assays
por: Kintigh, Jeremy, et al.
Publicado: (2017)

Emicizumab in tolerized patients with hemophilia A with inhibitors: A single‐institution pediatric cohort assessing inhibitor status
por: Batsuli, Glaivy, et al.
Publicado: (2021)

Clinical use of thrombin generation assays
por: Binder, Nikolaus B., et al.
Publicado: (2021)

Risk Factors for High-Titer Inhibitor Development in Children with Hemophilia A: Results of a Cohort Study
por: Halimeh, Susan, et al.
Publicado: (2013)

Correlations between patient-reported outcomes and self-reported characteristics in adults with hemophilia B and caregivers of children with hemophilia B: analysis of the B-HERO-S study
por: Buckner, Tyler W, et al.
Publicado: (2019)

A new hemophilia carrier nomenclature to define hemophilia in women and girls: Communication from the SSC of the ISTH
por: van Galen, Karin P. M., et al.
Publicado: (2021)

Optimizing language for effective communication of gene therapy concepts with hemophilia patients: a qualitative study
por: Hart, Daniel P., et al.
Publicado: (2021)

Molecular Mechanisms of Skewed X-Chromosome Inactivation in Female Hemophilia Patients—Lessons from Wide Genome Analyses
por: Dardik, Rima, et al.
Publicado: (2021)

Limited factor VIIa surface localization requirement of the factor VIIa–induced overall thrombin generation in platelet‐rich hemophilia A plasma
por: Persson, Egon, et al.
Publicado: (2019)

Regulation of coagulation by tissue factor pathway inhibitor: Implications for hemophilia therapy
por: Mast, Alan E., et al.
Publicado: (2022)

Inhibition of Intrinsic Thrombin Generation
por: Stief, Thomas W.
Publicado: (2006)

Thrombin Generation in Zebrafish Blood
por: Schurgers, Evelien, et al.
Publicado: (2016)

Editorial: Advances in thrombin generation
por: de Laat-Kremers, Romy, et al.
Publicado: (2023)

Response to “Studies on hemostasis in COVID‐19 deserve careful reporting of the laboratory methods, their significance and their limitation”: Don’t throw the baby out with the bathwater
por: Nougier, Christophe, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4mrjghtqrce0snfv0pd5ovrbuh